2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略

2019-03-11 美国心脏协会 Circulation. 2019 Mar 11.

2019年3月,美国心脏协会(AHA)发布了心肾综合征的分类,病理生理学,诊断和治疗策略的科学声明,心肾综合征包括一系列涉及心脏和肾脏的疾病,其中一个器官急性或慢性功能障碍可能导致另一个器官的急性或慢性功能障碍。本文主要总结了心肾综合征的分类,病理生理学,诊断和治疗策略的相关内容。

中文标题:

2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略

英文标题:

Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association.

发布机构:

美国心脏协会

发布日期:

2019-03-11

简要介绍:

2019年3月,美国心脏协会(AHA)发布了心肾综合征的分类,病理生理学,诊断和治疗策略的科学声明,心肾综合征包括一系列涉及心脏和肾脏的疾病,其中一个器官急性或慢性功能障碍可能导致另一个器官的急性或慢性功能障碍。本文主要总结了心肾综合征的分类,病理生理学,诊断和治疗策略的相关内容。 

拓展指南:肾脏相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略)] GetToolGuiderByIdResponse(projectId=1, id=604da1c001e175e7, title=2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略, enTitle=Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association., guiderFrom=Circulation. 2019 Mar 11., authorId=null, author=, summary=2019年3月,美国心脏协会(AHA)发布了心肾综合征的分类,病理生理学,诊断和治疗策略的科学声明,心肾综合征包括一系列涉及心脏和肾脏的疾病,其中一个器官急性或慢性功能障碍可能导致另一个器官的急性或慢性功能障碍。本文主要总结了心肾综合征的分类,病理生理学,诊断和治疗策略的相关内容。 , cover=, journalId=null, articlesId=null, associationId=60, associationName=美国心脏协会, associationIntro=美国心脏协会(AHA,American Heart Association)是心脏病学领域比较正要的学会之一,致力于心脏病和卒中的预防与治疗,提供相关继续教育、流行病学年度报告。每年举办学术年会报道中的的临床试验结果等,有官方杂志《美国心脏协会杂志》,提供心血管疾病和卒中相关的指南及专家共识,更新的比较快。, copyright=0, guiderPublishedTime=Mon Mar 11 00:00:00 CST 2019, originalUrl=, linkOutUrl=, content=<div>2019年3月,美国心脏协会(AHA)发布了心肾综合征的分类,病理生理学,诊断和治疗策略的科学声明,心肾综合征包括一系列涉及心脏和肾脏的疾病,其中一个器官急性或慢性功能障碍可能导致另一个器官的急性或慢性功能障碍。本文主要总结了心肾综合征的分类,病理生理学,诊断和治疗策略的相关内容。 </div> <div><br> </div> 拓展指南:<strong>与<font color=red>肾脏</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=6fb471c001e1381a" title="2019 接受肾脏保守治疗患者的护理建议-聚焦慢性肾病和症状的管理" target=_blank>2019 接受肾脏保守治疗患者的护理建议-聚焦慢性肾病和症状的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8880f1c0016e50b0" title="拟钙剂在慢性肾脏病患者中应用的专家共识" target=_blank>拟钙剂在慢性肾脏病患者中应用的专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=2e3231c0016a5ef2" title="2018 AISF/SIMI/SIMIT/SIN立场声明:慢性肾脏病患者丙型肝炎感染的管理" target=_blank>2018 AISF/SIMI/SIMIT/SIN立场声明:慢性肾脏病患者丙型肝炎感染的管理</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=8a6bf1c0016a48df" title="2018 KDIGO临床实践指南:慢性肾脏病患者丙型肝炎的预防,诊断,评估以及治疗" target=_blank>2018 KDIGO临床实践指南:慢性肾脏病患者丙型肝炎的预防,诊断,评估以及治疗</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=a6f561c001633397" title="2018 欧洲意见书:慢性肾脏疾病磁共振成像生物标志物" target=_blank>2018 欧洲意见书:慢性肾脏疾病磁共振成像生物标志物</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E8%82%BE%E8%84%8F" target=_blank>有关肾脏更多指南</a></ul>, tagList=[TagDto(tagId=2153, tagName=心肾综合征)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=14, categoryName=肾内科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=11559, appHits=486, showAppHits=24, pcHits=7401, showPcHits=5494, likes=149, shares=16, comments=7, approvalStatus=1, publishedTime=Thu Mar 28 23:49:29 CST 2019, publishedTimeString=2019-03-11, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Thu Mar 28 23:49:29 CST 2019, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 02:44:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略)])
2019 AHA科学声明:心肾综合征的分类,病理生理学,诊断和治疗策略
下载请点击:
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1203893, encodeId=a85512038933b, content=开拓新思路, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:11:17 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058030, encodeId=9e0c105803007, content=真棒,很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:16:49 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965199, encodeId=a41196519993, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210513/1967821a3cd949c8a85626c2420b462f/76467c03d4884d9da3d00d4bda328e6d.jpg, createdBy=bded1374056, createdName=成都, createdTime=Thu May 13 13:55:47 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883606, encodeId=3255883606b7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/30d5a3d1fbce4c40b47ed76f42ae8c89/033e39abdcf0450e9874c1f996d6fca9.jpg, createdBy=0c305213251, createdName=147646f9m27(暂无昵称), createdTime=Tue Sep 08 13:08:53 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364962, encodeId=077336496211, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:44 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2022-03-18 17326332

    开拓新思路

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1203893, encodeId=a85512038933b, content=开拓新思路, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:11:17 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058030, encodeId=9e0c105803007, content=真棒,很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:16:49 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965199, encodeId=a41196519993, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210513/1967821a3cd949c8a85626c2420b462f/76467c03d4884d9da3d00d4bda328e6d.jpg, createdBy=bded1374056, createdName=成都, createdTime=Thu May 13 13:55:47 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883606, encodeId=3255883606b7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/30d5a3d1fbce4c40b47ed76f42ae8c89/033e39abdcf0450e9874c1f996d6fca9.jpg, createdBy=0c305213251, createdName=147646f9m27(暂无昵称), createdTime=Tue Sep 08 13:08:53 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364962, encodeId=077336496211, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:44 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2021-10-06 ms3000001281480633

    真棒,很方便

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1203893, encodeId=a85512038933b, content=开拓新思路, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:11:17 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058030, encodeId=9e0c105803007, content=真棒,很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:16:49 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965199, encodeId=a41196519993, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210513/1967821a3cd949c8a85626c2420b462f/76467c03d4884d9da3d00d4bda328e6d.jpg, createdBy=bded1374056, createdName=成都, createdTime=Thu May 13 13:55:47 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883606, encodeId=3255883606b7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/30d5a3d1fbce4c40b47ed76f42ae8c89/033e39abdcf0450e9874c1f996d6fca9.jpg, createdBy=0c305213251, createdName=147646f9m27(暂无昵称), createdTime=Tue Sep 08 13:08:53 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364962, encodeId=077336496211, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:44 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2021-05-13 成都

    实用

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1203893, encodeId=a85512038933b, content=开拓新思路, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:11:17 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058030, encodeId=9e0c105803007, content=真棒,很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:16:49 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965199, encodeId=a41196519993, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210513/1967821a3cd949c8a85626c2420b462f/76467c03d4884d9da3d00d4bda328e6d.jpg, createdBy=bded1374056, createdName=成都, createdTime=Thu May 13 13:55:47 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883606, encodeId=3255883606b7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/30d5a3d1fbce4c40b47ed76f42ae8c89/033e39abdcf0450e9874c1f996d6fca9.jpg, createdBy=0c305213251, createdName=147646f9m27(暂无昵称), createdTime=Tue Sep 08 13:08:53 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364962, encodeId=077336496211, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:44 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2020-09-08 147646f9m27(暂无昵称)

    实用

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1203893, encodeId=a85512038933b, content=开拓新思路, beContent=null, objectType=guider, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9a512859481, createdName=17326332, createdTime=Fri Mar 18 21:11:17 CST 2022, time=2022-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1058030, encodeId=9e0c105803007, content=真棒,很方便, beContent=null, objectType=guider, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=5ace5622459, createdName=ms3000001281480633, createdTime=Wed Oct 06 08:16:49 CST 2021, time=2021-10-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=965199, encodeId=a41196519993, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210513/1967821a3cd949c8a85626c2420b462f/76467c03d4884d9da3d00d4bda328e6d.jpg, createdBy=bded1374056, createdName=成都, createdTime=Thu May 13 13:55:47 CST 2021, time=2021-05-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883606, encodeId=3255883606b7, content=实用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200908/30d5a3d1fbce4c40b47ed76f42ae8c89/033e39abdcf0450e9874c1f996d6fca9.jpg, createdBy=0c305213251, createdName=147646f9m27(暂无昵称), createdTime=Tue Sep 08 13:08:53 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=364962, encodeId=077336496211, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d2622354286, createdName=122b9cbbm13暂无昵称, createdTime=Sat Apr 20 12:34:44 CST 2019, time=2019-04-20, status=1, ipAttribution=)]
    2019-04-20 122b9cbbm13暂无昵称

    谢谢

    0